Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,732
  • Shares Outstanding, K 10,636
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,160 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.80
  • Most Recent Earnings $-0.83 on 11/14/25
  • Next Earnings Date 02/20/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -1.66
  • Growth Rate Est. (year over year) +86.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4011 +34.36%
on 02/02/26
0.8000 -32.64%
on 01/07/26
-0.2551 (-32.13%)
since 01/06/26
3-Month
0.4011 +34.36%
on 02/02/26
1.1500 -53.14%
on 11/14/25
-0.0146 (-2.64%)
since 11/06/25
52-Week
0.4011 +34.36%
on 02/02/26
3.8500 -86.00%
on 06/27/25
-1.6511 (-75.39%)
since 02/06/25

Most Recent Stories

More News
GT Biopharma Submits IND for Solid Tumor Immunotherapy Targeting Portion of $362 Billion Market as Cash Position Nearly Triples

GT Biopharma announced it has submitted an IND to the FDA for GTB-5550, its third NK cell engager entering clinical development for B7-H3–expressing solid tumors, while reporting a strengthen

GTBP : 0.5389 (+8.54%)
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans

GT Biopharma (GTBP) received FDA clearance to begin human trials of its TriKE®-based cancer therapy GTB-5550, marking a strategic expansion from blood cancers into the much larger solid tumor market by...

GTBP : 0.5389 (+8.54%)
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January...

GTBP : 0.5389 (+8.54%)
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend...

GTBP : 0.5389 (+8.54%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 84.49 (+4.74%)
KPTI : 6.26 (+2.79%)
GTBP : 0.5389 (+8.54%)
GSK : 60.23 (+1.79%)
TAK : 17.89 (+0.51%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 18.00 (+6.01%)
GTBP : 0.5389 (+8.54%)
ROIV : 25.82 (+22.14%)
CCCC : 1.8200 (+6.43%)
BMY : 61.99 (+4.15%)
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026...

GTBP : 0.5389 (+8.54%)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.53 (+7.20%)
GMAB : 30.90 (-0.23%)
NRIX : 16.85 (+5.64%)
GTBP : 0.5389 (+8.54%)
SLS : 3.73 (+5.67%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 40.83 (+6.44%)
ARAY : 0.6200 (+3.32%)
KURA : 7.83 (+5.81%)
GTBP : 0.5389 (+8.54%)
TNGX : 12.51 (+4.69%)
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The convergence of advanced diagnostics and targeted therapeutics is reshaping cancer care, as September 2025...

LNTH : 64.89 (+0.05%)
GEHC : 80.65 (-2.02%)
SNDX : 21.01 (+4.27%)
IOBT : 0.3500 (+9.27%)
GTBP : 0.5389 (+8.54%)

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 0.6529
2nd Resistance Point 0.5964
1st Resistance Point 0.5677
Last Price 0.5389
1st Support Level 0.4825
2nd Support Level 0.4260
3rd Support Level 0.3973

See More

52-Week High 3.8500
Fibonacci 61.8% 2.5325
Fibonacci 50% 2.1256
Fibonacci 38.2% 1.7186
Last Price 0.5389
52-Week Low 0.4011

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar